Staar Surgical Celebrates Three Million Implantable Collamer Lenses

Staar Surgical announced that more than 3 million Implantable Collamer Lens (ICLs) have been sold globally.[1]

“We extend our sincere gratitude to the surgeons and clinicians with whom we partner and to their patients who have chosen our ICLs for their vision correction as we celebrate our 3 million lens milestone,” Tom Frinzi, President and CEO of STAAR Surgical, said in a company news release. “EVO ICL is the next logical step in refractive innovation with clear differentiators in patient outcomes and satisfaction. Our lens-based technology is ushering in the next generation of vision correction by helping to free patients from the struggle of daily contacts and eyeglasses.” 

EVO ICL is an implantable lens designed to correct a wide range of vision correction needs, including myopia with and without astigmatism, through a minimally invasive procedure. The EVO ICL lens is implanted between the iris and the natural crystalline lens in a quick and safe 20-30 minute procedure. It’s biocompatible and does not remove corneal tissue, so it works with the natural eye, and the lens implant is removable by a surgeon, if desired. 

In October 2023, Staar Surgical celebrated the 30th anniversary of its proprietary ICL. The first ICLs were implanted by a group of surgeons in October 1993, including Roberto Zaldivar, MD, Founder of the Zaldivar Institute. The early ICLs have evolved into the current generation of ICLs with a central port—the EVO ICL family of lenses.

Staar began selling the ICL in 1996. The ICL with the central port (EVO ICL) was first approved for commercial use in CE Mark countries in 2011 and in the United States in 2022.

Reference

1 EVO ICL accounts for approximately 2.5 million of the 3 million total ICLs sold.